Novel Therapeutic Agents in Pediatric Sepsis - Zinc

Jeffrey E. Nowak* and Hector R. Wong

1Division of Critical Care Medicine, Cincinnati Children’s Hospital Medical Center, The Kindervelt Laboratory for Critical Care Medicine Research, Cincinnati Children’s Research Foundation; 2Department of Pediatrics, University of Cincinnati College of Medicine, USA

Abstract: Zinc status and infections are closely inter-related. For nearly half a century, the effects that zinc depletion has on the status of the immune system has been slowly elucidated. More recently, the effects that infection and sepsis have on an organism's zinc supplies have begun to be recognized and potential therapeutic intervention in this zinc/infection interplay are beginning to be explored. The literature related to these areas is reviewed, and possible future directions are discussed.

Keywords: Zinc, sepsis, immunity, genomics, therapeutics.

INTRODUCTION

The understanding of the role of zinc in infections and sepsis has been evolving over the past 40-50 years, with interest in the possible therapeutic use of zinc burgeoning in the past decade. Initial clues to the importance of zinc came from clinical deficiency states [1-3]. Subsequently, the important role that zinc plays in a properly functioning immune system has been increasingly recognized, as have many of the mechanistic underpinnings of this relationship [1]. Lastly, recognition of perturbations in zinc status in populations not previously thought to be zinc deficient (including pediatric patients with septic shock) [4] has led to interest in the use of zinc as a therapeutic tool which could be more broadly applied for sepsis.

INFECTIONS IN HUMAN ZINC DEFICIENCY STATES

Clinical zinc deficiency in humans was first described in 1963 in relation to a syndrome involving iron deficiency anemia, hepatosplenomegally, dwarfism, and hypogonadism [3]. Those who studied this syndrome noted that the subjects suffered from premature death, which appeared to be due to infectious causes, though the investigators lacked the proper facilities in the field to pursue this hypothesis [1].

In the developed world, clinical zinc deficiency is typically recognized only in cases of Acrodermatitis Enteropathica. This condition was initially described in 1942 as a syndrome involving diarrhea, dermatitis, and alopecia [5]. Prior to elucidation of the critical role of zinc in this disorder, reported cases typically died of sepsis [6,7]. In the mid-1970s acrodermatitis enteropathica came to be understood as a disorder of zinc deficiency which could be alleviated through oral zinc supplementation [8-11]. Subsequent investigations have revealed that acrodermatitis enteropathica is an autosomal recessive disorder which is due to a defect in the gene coding for the Zip4 transporter protein, leading to impaired intestinal absorption of zinc [12]. With normalization of zinc status, patients have a normal lifespan and no apparent predisposition to sepsis.

Iatrogenic zinc deficiency in humans was created through early formulations of total parenteral nutrition, which were deficient in trace minerals [13]. Likely due to the timely recognition and correction of the underlying zinc deficiency, these patients were not reported to develop sepsis. However, those who were studied during their zinc deficiency were found to have depressed T-cell function, which was reversed with zinc supplementation [14-16].

ROLE OF ZINC IN THE IMMUNE SYSTEM

The significance of infectious complications in zinc deficiency states has led to considerable research into the role that zinc plays in the immune system. Though much remains to be learned, it is clear that perturbations in zinc concentrations have specific effects on both the innate and adaptive arms of the immune response, as will be discussed below. Additionally, it has recently been shown that zinc depletion can impair NF-κB activation, which has downstream implications for both arms [17].

Zinc and the Innate Immune System

Zinc status has been shown to affect multiple cells of the innate immune system. Over 25 years ago mild zinc deficiency secondary to hemodialysis was shown to decrease the chemotactic response of neutrophils ex-vivo [18]. Similarly, mild human zinc deficiency has been shown to decrease the number [19] and ex-vivo function [20] of NK cells. From a mechanistic standpoint, it has been shown that...
zinc induces the adhesion of myelomonocytic cells to endothelial cells as well as extracellular matrix proteins, critical steps in chemotaxis [21].

**Zinc and the Adaptive Immune System**

Zinc deficiency in humans or rodents leads to lymphopenia through increased apoptosis of pre-B and pre-T cells, with mature B and T cells being relatively resistant [22]. This lymphopenia causes the organism as a whole to display impaired antibody production [23,24] however, the B cells that remain do not show decreased antibody production on a per cell basis [24].

Zinc has multiple effects on T-cell function. On a gross level, zinc deficiency results in thymic atrophy, which is reversible with supplementation [25]. Further, zinc is an essential cofactor for thymulin, a hormone which has multiple effects, including: regulation of immature T-cell differentiation in the thymus; induction of proliferation of CD8+ T-cells; and promotion of T-cell function [1,26]. Even mild zinc depletion in humans has been shown to decrease thymulin activity, which was subsequently restored with supplementation [27]. Finally, zinc deficiency leads to an alteration of the Th1:Th2 balance through decreases in the Th1 cytokines [28].

**HUMAN ZINC SUPPLEMENTATION**

Depressed zinc levels are found in multiple populations of patients who have an increased susceptibility to infections, including (but not limited to) patients with trisomy 21 [29], hemoglobin SS [30], Acquired Immunodeficiency Syndrome [31], hepatic cirrhosis [32], and the elderly [33]. Trials of oral zinc supplementation in each these populations have demonstrated improvement in markers of immune function [29,31-35]. Additionally, zinc supplementation has produced a decrease in the incidence of infection in all of these populations (except those with cirrhosis, who were not studied for this endpoint), even leading to a decrease in hospitalizations among patients with hemoglobin SS [30,31,36,37].

Children in developing countries are at risk of trace element deficiency. Noting that deficiency in zinc may worsen diarrheal illness and susceptibility to infections, members of the Department of International Health at John’s Hopkins have partnered with agencies in these countries to study the effect of oral zinc supplementation in large numbers of at risk children. Indian children from 6-35 months of age who presented with acute diarrhea and were supplemented with 20 mg of elemental zinc daily had decreased severity and duration of diarrhea compared with children who received placebo [38]. Once the children in this study had resolution of their diarrheal illness, their dose of zinc (or placebo) was halved, and they were followed for an additional six months to assess the burden of acute lower respiratory infections. Daily oral supplementation of 10 mg of elemental zinc decreased both the incidence (by 45%) and the prevalence (by 40%) of acute lower respiratory tract infections in this population [39]. A separate study of over 42,000 children aged 1-48 months in Zanzibar to evaluate the effect of prophylactic zinc (vs. placebo) on mortality showed a non-significant trend toward decreased mortality in the zinc supplementation group as a whole (relative risk 0.93; p = 0.294) [40]. An a priori planned subgroup analysis of these data showed a significant reduction of the mortality rate for children aged 12-48 months who received zinc supplementation (relative risk 0.82; p = 0.045), which was driven primarily by a decrease in infection-related deaths [40].

**ZINC IN SEPSIS AND CRITICAL ILLNESS**

Modern computing and microarray genomic expression technology allow for the collection and analysis of vast amounts of data. This makes possible the design of hypothesis-generating studies and the resultant discovery of unexpected findings, which may have been missed with targeted, hypothesis-driven studies. The Genomics in Pediatric SIRS/Septic Shock Investigators have developed a multi-site study of the genomic response to septic shock, sepsis, or the systemic inflammatory response syndrome (SIRS) in the pediatric population which utilizes this hypothesis-generating strategy. Initial data from this study revealed that pediatric septic shock is associated with widespread downregulation of the expression of genes related to zinc and metal binding [4]. This repression pattern has subsequently been validated in a separate cohort of pediatric patients with septic shock [41], and has been shown to persist through at least day three of illness [42]. The most recent analysis shows that this repression pattern is not seen in pediatric patients with SIRS or sepsis, rather, it appears to be specific for patients with septic shock [43].

In addition to the downregulation of zinc related genes in pediatric septic shock patients, the population of patients who subsequently died displayed an upregulation of two isoforms of metallothionein, when compared with patients who survived the episode of septic shock [4]. This is noteworthy, as metallothioneins can bind and sequester zinc intracellularly, and thus their upregulation could lead to a decrease in the serum levels and bioavailability of zinc.

These data were then followed up with further, hypothesis-driven investigation. Measurement of serum zinc levels showed that these levels were normal in the population of children who survived their septic shock, whereas they were significantly lower in those children who subsequently died [4]. Additionally, a study done using metallothionein-null mice showed that these mice had a survival advantage following polymicrobial sepsis, when compared with wild-type controls [4]. This suggests that the upregulation of metallothionein isoforms seen in children who died of septic shock is, in fact, maladaptive.

Induction of sepsis in animal models allows for more controlled study of the interaction between zinc status and response to sepsis. Diet-induced sub-acute zinc deficiency in mice has been shown to increase mortality from sepsis resulting from either parasitemia [44] or polymicrobial intra-abdominal infection [45]. The zinc-deficient mice subjected to polymicrobial sepsis displayed increased production of pro-inflammatory cytokines and increased tissue damage in their lungs and spleens, when compared to control mice subjected to the same insult [45]. Mice who were made zinc-deficient for 3 weeks, but then had their zinc levels repleted in the 3 days preceding infection had cytokine levels and tissue damage similar to control mice, however, their survival rate was in between that of the control and zinc.
deficient mice [45]. This suggests that the survival disadvantage conferred by zinc deficiency likely results from a combination of both the acute response to infection (such as increased inflammation and decreased anti-oxidant capacity) and the longer-term sequellae of zinc deficiency (such as lymphopenia or alterations of the genome expression pattern).

To date, no human studies of zinc supplementation in patients with sepsis have been published, however, data regarding zinc supplementation in patients with critical illness are available. Heyland et al. recently published a meta-analysis of randomized clinical trials of zinc supplementation in mechanically ventilated, critically ill adults [46]. Four studies—consisting of trauma and large (>20% body surface area) burns—met their criteria. Their analysis indicated that zinc supplemented patients had a trend toward decreased mortality (relative risk = 0.63), however, the sample size and variability precluded statistical significance (p = 0.33) [46]. In a separate, single-center study of antioxidant and glutamine supplementation of mechanically ventilated, hypoperfused adults Heyland et al. provided varying levels of enteral zinc supplementation, either none (n = 7), 10 mg (n = 7), or 20 mg (n = 14) of elemental zinc per day [47]. Neither of the supplemental doses restored normal zinc levels in these patients, but they did result in a trend toward increased serum zinc levels, whereas the group which received no supplemental zinc had a decrease in their serum zinc levels [46]. Further, analysis of zinc levels over time revealed that survivors had an increase in their zinc levels over time, which was significantly different from nonsurvivors, whose zinc levels did not increase [46].

**FUTURE DIRECTIONS**

Given the biological underpinnings, and the preliminary data in critically ill patients, a logical next step is a randomized, controlled trial of zinc supplementation in patients with sepsis and/or septic shock. When considering or conducting such a study, one must be open to the fact that the alterations seen in zinc status may be adaptive—therefore, zinc supplementation may lead to a worse outcome. There is some in-vitro evidence which suggests that zinc may enhance bacterial virulence [48], and clinical experience with iron demonstrates the complexity involved in predicting the response to therapeutic manipulation of trace element status in the face of infections. Chelation of iron has been shown to improve outcome in children with cerebral malaria [49]. Also, the oral supplementation trial in Zanzibar referenced earlier initially included arms containing iron and folic acid supplementation which were stopped early due to an increase in the rate of hospitalization or death [50]. The important difference between supplementation of iron and zinc is highlighted by the fact that (as mentioned above) this same trial in Zanzibar showed that zinc supplementation lead to decreased mortality [40]. Likewise, iron supplementation has been reported to increase mortality in a murine model of polymicrobial sepsis [51], whereas preliminary data from our laboratory indicate that zinc supplementation decreases mortality in such a model. Furthermore, the survival benefit seen in metallothionein-null mice and the decreased serum zinc levels in pediatric patients who died from septic shock relative to those who survived septic shock both indicate that the lowered plasma zinc levels seen in these patients are not likely due to an adaptive response [4]. Taking into account all of the available evidence, a therapeutic trial appears to be warranted.

Questions regarding a possible study that need to be addressed are the proper route, dose, and duration of therapy. For the sake of reliability, the intravenous route should be the preferred method of zinc delivery, given the variable bioavailability of zinc when it is provided enterally [52]. Determining the proper dose and duration of zinc supplementation is more difficult. Two studies indicate that 20 mg of elemental zinc per day provided enterally to critically ill adults (300 mcg/kg/day assuming a typical adult weight of 70 kg) does not consistently restore plasma zinc levels to normal [46,53]. Similarly, intravenous supplementation of severely burned adults with 37.5 mg of elemental zinc per day (540 mcg/kg/d) for 8 days following severe burns resulted in a somewhat less pronounced serum zinc deficiency than that of control patients, but did not hasten the return to normal zinc levels, which occurred on post-burn day 20 in both groups [54]. Thus, it appears that supplementation should be done with doses greater than 600 mcg/kg/day; however, some caution must be exercised, as high concentrations of zinc could depress immune function. In vitro, high concentrations of zinc have been shown to decrease T-cell proliferation through inhibition of IL-1 receptor-associated protein kinase [55]. A dose of 300 mg/day (4,300 mcg/kg/day) given enterally to healthy adult males for 42 days caused a decrease in ex-vivo neutrophil chemotaxis and phagocytosis [56]; and a dose of 1,900 mcg/kg/day (± 300 mcg/kg/day) given enterally to infants recovering from marasmus impaired phagocytosis and fungicidal activity in ex-vivo monocytes after 60 and 105 days of supplementation, respectively [57]. It is noteworthy that both of these studies showing decreased ex-vivo immune function studied the effects of relatively long-term supplementation, and that the study of marasmic infants was also purported to show that zinc supplementation resulted in improvement of other measures of immune function (delayed hypersensitivity skin reactions, lymphoproliferative response to phytohemagglutinin, and salivary IgA concentrations), as well as improvement of linear growth [58]. In contrast to these long-term supplementation experiments, a study of 150 mg/day (2,140 mcg/kg/day) of elemental zinc given enterally to severely burned adults demonstrated a decreased time to wound healing without any adverse effects (though no ex-vivo studies were done) [59]. When taking into account all of the above, along with preliminary data from our lab regarding parenteral supplementation of zinc in mice subjected to polymicrobial sepsis, we believe that a reasonable zinc supplementation regimen would be a dose in the range of 1,000-2,000 mcg/kg/day of elemental zinc administered intravenously for 7 to 10 days.

**CONCLUSIONS**

The understanding of zinc metabolism and its role in a properly functioning immune system has increased steadily throughout the past 50 years. It is clear that zinc plays a pivotal role in the immune response, and that perturbations in zinc status adversely impact outcome following infection.
Hopefully, we will soon be able to leverage this increased understanding into therapeutic interventions which will improve the outcome of pediatric sepsis.

REFERENCES


